Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer
Stacey J. Winham(Mayo Clinic), Jonathan P. Tyrer(University of Cambridge), Maria Bisogna(Memorial Sloan Kettering Cancer Center), Julie M. Cunningham(Cancer Research UK), Zachary C. Fogarty(Mayo Clinic in Florida), Y. Ann Chen(Zhejiang Chinese Medical University), Yukie T. Bean(Oregon Health & Science University), Elisa V. Bandera(Rutgers, The State University of New Jersey), Allan Jensen(Danish Cancer Society), Honglin Song(University of Cambridge), Michael E. Carney(The University of Texas MD Anderson Cancer Center), Jan Lubiński(Tumour Institute of Tuscany), Anna DeFazio(The University of Sydney), Hui‐Yi Lin(Moffitt Cancer Center), Madalene A. Earp(Mayo Clinic in Florida), Douglas A. Levine(New York University), Susanne K. Kjær(Copenhagen University Hospital), Marc T. Goodman(Cedars-Sinai Medical Center), Simon A. Gayther(The University of Texas Health Science Center at Houston), Aleksandra Gentry‐Maharaj(UCL Australia), Susan J. Ramus(Cancer Institute of New South Wales), Ed Dicks(Institute of Cancer Research), Kathryn L. Terry(Brigham and Women's Hospital), Kirsten B. Moysich(American Cancer Society), Daniel W. Cramer(Brigham and Women's Hospital), Nicolas Wentzensen(National Cancer Institute), Irene Orlow(Memorial Sloan Kettering Cancer Center), Malcolm C. Pike(Kettering University), Louise A. Brinton(National Cancer Institute), Tanja Pejović(Oregon Health & Science University), Jennifer A. Doherty(Cancer Prevention Institute of California), Francesmary Modugno(University of Pittsburgh), Hoda Anton‐Culver(University of California, Irvine), Usha Menon(University of South Florida), Beth Y. Karlan(University of California, Los Angeles), Cezary Cybulski(International Hereditary Cancer Center), Jacek Gronwald(International Hereditary Cancer Center), Melissa C. Larson(Mayo Clinic), Celeste Leigh Pearce(University of Southern California), Sharon E. Johnatty(University of Southern California), Pamela J. Thompson(University of Southern California), Mary Anne Rossing(Fred Hutch Cancer Center), Jenny Lester(Cedars-Sinai Medical Center), Edwin S. Iversen(Mayo Clinic), Roberta B. Ness(The University of Texas Health Science Center at Houston), Ailith Pirie(University of Cambridge), Robert P. Edwards(Magee-Womens Research Institute), Jolanta Lissowska, Martin Gore(Imperial College London), Janusz Menkiszak(Pomeranian Medical University)
Cited by 15
Related Papers
Mutations of the BRAF gene in human cancer
|Nature|2002|10.7k
Integrated genomic analyses of ovarian carcinoma
|Nature|2011|8.2k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Patterns of somatic mutation in human cancer genomes
|Nature|2007|3.1k